Strategies to manage hepatitis C virus (HCV) infection disease burden - Volume 2

Journal of Viral Hepatitis

Volumn 22, Issue s1, 2015, Pages 46-73

  Gane, E ^a   Kershenobich, D ^b   Seguin Devaux, C ^c   Kristian, P ^d   Aho, I ^e   Dalgard, O ^f   Shestakova, I ^g,h   Nymadawa, P ⁱ   Blach, S ^j   Acharya, S ^k   Anand, A C ^l   Andersson, M I ^m   Arendt, V ⁿ   Arkkila, P ^e   Baatarkhuu, O ^o   Barclay, K ^p   Ben Ari, Z ^q   Bergin, C ^r,s   Bessone, F ^t   Blokhina, N ^u   Brunton, C R ^v   Choudhuri, G ^w   Chulanov, V ^x   Cisneros, L ^y   Croes, E A ^z   Dahgwahdorj, Y A ^o   Daruich, J R ^aa   Dashdorj, N R ^ab   Davaadorj, D ^o   De Knegt, R J ^ac   De Vree, M ^ad   Gadano, A C ^ae   Gower, E ^j   Halota, W ^af   Hatzakis, A ^ag   Henderson, C ^ah   Hoffmann, P ^ai   Hornell, J ^p   Houlihan, D ^aj   Hrusovsky, S ^ak,al   Jarcuska P ^d   Kostrzewska, K ^am   Leshno, M ^q   Lurie, Y ^an   Mahomed, A ^ao   Mamonova, N ^ap   Mendez Sanchez, N ^aq   Mossong, J ^ar   Norris, S ^r   Nurmukhametova, E ^u   Oltman, M ^as   Oyunbileg, J ^at   Oyunsuren, Ts ^au   Papatheodoridis, G ^ag   Pimenov, N ^x   Prins, M ^av,aw   Puri, P ^ax   Radke, S ^ay,az   Rakhmanova, A ^ba   Razavi, H ^j   Razavi Shearer, K ^j   Reesink, H W ^aw   Ridruejo, E ^bb   Safadi, R ^bc   Sagalova, O ^bd   Sanchez Avila, J F ^b   Sanduijav, R ^at   Saraswat, V ^be   Schreter I ^d   Shah, S R ^bf   Shevaldin, A ^af   Shibolet, O ^q,bg   Silva, M O ^bh   Sokolov, S ^bi   Sonderup, M ^bj   Souliotis, K ^bk   Spearman, C W ^bl   Staub, T ⁿ   Stedman, C ^bm   Strebkova, E A ^bn   Struck, D ^c   Sypsa, V ^ag   Tomasiewicz, K ^bo   Undram, L ^o   Van Der Meer, A J ^ac   Van Santen, D ^bq   Veldhuijzen, I ^br   Villamil, F G ^bs   Willemse, S ^aw   Zuckerman, E ^bt   Zuure, F R ^av   Prabdial Sing, N ^bq,bu   Flisiak, R ^bp   Estes, C ^j   more..

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^d P J AFÁRIK UNIVERSITY   (Slovakia)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^g A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

^h N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

ⁱ Mongolian Academy of Medical Sciences   (Mongolia)

^j Center for Disease Analysis   (United States)

^k ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^l INDRAPRASTHA APOLLO HOSPITAL   (India)

^m UNIVERSITY OF STELLENBOSCH   (South Africa)

ⁿ CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^o MONGOLIAN NATIONAL UNIVERSITY OF MEDICAL SCIENCES   (Mongolia)

^p The Hepatitis Foundation of New Zealand   (New Zealand)

^q TEL AVIV UNIVERSITY   (Israel)

^r ST JAMES S HOSPITAL   (Ireland)

^s TRINITY COLLEGE DUBLIN   (Ireland)

^t UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^u Infectious Diseases Hospital   (Russian Federation)

^v CANTERBURY DISTRICT HEALTH BOARD   (New Zealand)

^w Fortis Memorial Research Institute   (India)

^x CENTRAL RESEARCH INSTITUTE OF EPIDEMIOLOGY   (Russian Federation)

^y INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^z NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^aa HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^ab Onom Foundation   (Mongolia)

^ac ERASMUS MEDICAL CENTER   (Netherlands)

^ad UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^ae HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^af Department of Gastroenterology and Hepatology Mongolian National University of Medical Sciences ^*  (Russian Federation)

^ag UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^ah Needle Exchange Programme New Zealand   (New Zealand)

^ai Directorate of Health   (Luxembourg)

^aj ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^ak SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^al 1st Department of Internal Medicine   (Slovakia)

^am HTA CONSULTING   (Poland)

^an SHAARE ZEDEK MEDICAL CENTER   (Israel)

^ao UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^ap Research and Diagnostic Center for Clinical Psychiatry   (Russian Federation)

^aq LIVER RESEARCH UNIT   (Mexico)

^ar LABORATOIRE NATIONAL DE SANTÉ   (Luxembourg)

^as Gastroenterology and Hepatology Center   (Slovakia)

^at National Center for Communicable Diseases   (Mongolia)

^au INSTITUTE OF CHEMISTRY AND CHEMICAL TECHNOLOGY   (Mongolia)

^av DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^aw ACADEMIC MEDICAL CENTER   (Netherlands)

^ax ARMY HOSPITAL RESEARCH AND REFERRAL   (India)

^ay INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^az UNIVERSITY OF AUCKLAND   (New Zealand)

^ba St Petersburg AIDS Center   (Russian Federation)

^bb CEMIC   (Argentina)

^bc HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^bd SOUTH URAL STATE MEDICAL UNIVERSITY   (Russian Federation)

^be SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^bf Global Hospital   (India)

^bg TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^bh UNIVERSIDAD AUSTRAL   (Argentina)

^bi Tyumen Regional State Autonomous Healthcare Institution Consulting and Diagnostic Centre   (Russian Federation)

^bj UNIVERSITY OF CAPE TOWN   (South Africa)

^bk UNIVERSITY OF PELOPONNESE   (Greece)

^bl UNIVERSITY OF CAPE TOWN   (South Africa)

^bm UNIVERSITY OF OTAGO   (New Zealand)

^bn SAMARA STATE MEDICAL UNIVERSITY   (Russian Federation)

^bo MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^bp MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^bq UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^br Public Health Service Rotterdam Rijnmond   (Netherlands)

^bs HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^bt TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^bu NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

more..

Author keywords

diagnosis; disease burden; epidemiology; HCV; hepatitis C; incidence; mortality; prevalence; scenarios; treatment

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; RIBAVIRIN;

ARTICLE; EPIDEMIC; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; NONHUMAN; PREVALENCE; SCREENING; BIOLOGICAL MODEL; COST OF ILLNESS; DISEASE COURSE; HEALTH; HEPATITIS C, CHRONIC; MASS SCREENING; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COST OF ILLNESS; DISEASE PROGRESSION; GLOBAL HEALTH; HEPATITIS C, CHRONIC; HUMANS; MASS SCREENING; MODELS, BIOLOGICAL; PREVALENCE; TREATMENT OUTCOME;

EID: 84920279600     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12352     Document Type: Article

References (37)

1. Hatzakis A, Chulanov VP, Gadano AC,. The present and future disease burden of hepatitis C virus (HCV) with today's treatment paradigm-volume 2. J Viral Hepat 2014; Forthcoming.
2. Razavi H, Waked I, Sarrazin C, et al,. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 Suppl 1: 34-59.
3. Evon DM, Verma A, Dougherty KA, et al,. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci 2007; 52: 3251-3258.
4. Morrill JA, Shrestha M, Grant RW,. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005; 20: 754-758.
5. North CS, Hong BA, Adewuyi SA, et al,. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry 2013; 35: 122-128.
6. Saraswat V, Norris S, Zuckerman E,. Historical epidemiology of hepatitis C virus (HCV) in select countries-volume 2. J Viral Hepat 2014; Forthcoming.
7. Flichman DM, Blejer JL, Livellara BI, et al,. Prevalence and trends of markers of hepatitis B virus, hepatitis C virus and human Immunodeficiency virus in Argentine blood donors. BMC Infect Dis 2014; 14: 218.
8. Fassio E, Schroder T,. Statement of the Argentinian Concensus on Hepatitis C 2007. Acta Gastroenterol Latinoam 2008; 38: 56-74.
9. Sari J, Outi L, Ruska RF, et al,. Infectious Diseases in Finland, 2012. Report No. 12. Helsinki, Finland: National Institute for Health and Welfare (THL), 2013.
10. Papatheodoridis G, Sypsa V, Kantzanou M, Nikolakopoulos I, Hatzakis A,. Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey. J Viral Hepat 2014; Forthcoming.
11. Thornton L, Murphy N, Jones L, et al,. Determination of the burden of hepatitis C virus infection in Ireland. Epidemiol Infect 2012; 140: 1461-8.
12. Health Protection Surveillance Centre. EMI guidelines-Appendix 23 hepatitis C virus: epidemiology and transmission risks. 2012.
13. Health Protection Surveillance Centre. National Hepatitis C Database for infection acquired through blood and blood products. 2010.
14. Mendez-Sanchez N, Garcia-Villegas E, Merino-Zeferino B, et al,. Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: a retrospective study of the nation and the federal states. Ann Hepatol 2010; 9: 428-438.
15. Mendez-Sanchez N, Villa AR, Chavez-Tapia NC, et al,. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005; 4: 52-55.
16. Mendez-Sanchez N,. The socioeconomic impact of hepatitis C infection and liver transplantation in Mexico. Ann Hepatol 2012; 11: 550-551.
17. Mendez-Sanchez N, Aguilar-Ramirez JR, Reyes A, et al,. Etiology of liver cirrhosis in Mexico. Ann Hepatol 2004; 3: 30-33.
18. Hernandez-Dominguez JM, Holm-Corzo A, Santos-Caballero M, et al,. [Experience in liver transplantation (1996-2011) at the UMAE, General Hospital Gaudencio Gonzalez Garza, National Medical Center La Raza, Mexican Institute of Social Security, Mexico City, D.F.]. Rev Invest Clin 2011; 63 (Suppl 1): 62-66.
19. Cisneros-Garza LE, Lopez-Hernandez PA, Munoz-Ramirez MR, et al,. [Liver transplant at the UMAE 25 IMSS Monterrey]. Rev Invest Clin 2011; 63 (Suppl 1): 67-72.
20. Perez-Rodriguez E, Munoz-Espinosa LE, Zapata-Chavira H, et al,. [Orthotopic liver transplantation. Experience in the University Hospital of Monterrey, N.L.]. Rev Invest Clin 2011; 63 (Suppl 1): 79-84.
21. Rodriguez-Montalvo C, Tijerina-Gomez L, Flores-Villalba E, et al,. [Twelve years of liver transplant at the San Jose-Tec De Monterrey Hospital]. Rev Invest Clin 2011; 63 (Suppl 1): 73-78.
22. Dondog B, Lise M, Dondov O, Baldandorj B, Franceschi S,. Hepatitis B and C virus infections in hepatocellular carcinoma and cirrhosis in Mongolia. Eur J Cancer Prev 2011; 20: 33-39.
23. GIPdatabank. Aantal gebruikers 2008-2012 voor ATC-subgroep J05AB04: Ribavirin. 2013. Available at: https://www.gipdatabank.nl/databank.asp (accessed 27 November 2013).
24. GIPdatabank. Aantal gebruikers 2009-2013 voor ATC-subgroep J05AB04: Ribavirin. 2014. Available at: https://www.gipdatabank.nl/databank.asp (accessed 16 July 2014).
25. Nesdale A, Baker M, Gane E, et al,. Hepatitis C infection in New Zealand: estimating the current and future prevalence and impact. 2000.
26. The Hepatitis Foundation of New Zealand. Hepatitis C. 2013. Available at: http://www.hepatitisfoundation.org.nz/index.php/hepc/ (accessed 17 February 2014).
27. Institute of Environmental Science and Research Limited. Notifiable and other diseases in New Zealand: annual report 2012. Report No. FW13014. 2013.
28. Viral Hepatitis in Russian Federation. Analytical Review, 9th edn. 2013: 113.
29. Ward JW,. The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease. Top Antivir Med 2013; 21: 15-19.
30. Smith BD, Morgan RL, Beckett GA, et al,. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1-32.
31. Rein DB, Smith BD, Wittenborn JS, et al,. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156: 263-270.
32. Vladimirsky S, Silvina MM, Otegui L, et al,. [Surveillance of viral hepatitis in Argentina: analysis of information from sentinel units 2007-2010]. Acta Gastroenterol Latinoam 2013; 43: 22-30.
33. Raptopoulou M, Touloumi G, Tzourmakliotis D, et al,. Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study. Hippokratia 2011; 15: 26-31.
34. Burguete-Garcia AI, Conde-Gonzalez CJ, Jimenez-Mendez R, et al,. Hepatitis C seroprevalence and correlation between viral load and viral genotype among primary care clients in Mexico. Salud Publica Mex 2011; 53 (Suppl 1): S7-S12.
35. Chlabicz S, Flisiak R, Grzeszczuk A, Kovalchuk O, Prokopowicz D, Chyczewski L,. Known and probable risk factors for hepatitis C infection: a case series in north-eastern Poland. World J Gastroenterol 2006; 12: 141-145.
36. Backus LI, Boothroyd DB, Phillips BR, Mole LA,. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46: 37-47.
37. Aleman S, Rahbin N, Weiland O, et al,. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013; 57: 230-236.